
## Vanesa Nozal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/124754/publications.pdf Version: 2024-02-01



VANESA NOZAL

#	Article	IF	CITATIONS
1	COVID-19: Drug Targets and Potential Treatments. Journal of Medicinal Chemistry, 2020, 63, 12359-12386.	2.9	348
2	TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2019, 10, 1183-1196.	1.7	37
3	Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases. European Journal of Medicinal Chemistry, 2019, 161, 39-47.	2.6	29
4	Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology, 2021, 178, 1316-1335.	2.7	28
5	Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods. Pharmaceuticals, 2021, 14, 332.	1.7	21
6	TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Journal of Medicinal Chemistry, 2022, 65, 1585-1607.	2.9	20
7	Improved Controlled Release and Brain Penetration of the Small Molecule S14 Using PLGA Nanoparticles. International Journal of Molecular Sciences, 2021, 22, 3206.	1.8	15
8	Increasing Brain Permeability of PHA-767491, a Cell Division Cycle 7 Kinase Inhibitor, with Biodegradable Polymeric Nanoparticles. Pharmaceutics, 2021, 13, 180.	2.0	10
9	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie - International Edition, 2021, 60, 19344-19354.	7.2	9
10	From Kinase Inhibitors to Multitarget Ligands as Powerful Drug Leads for Alzheimer's Disease using Proteinâ€Templated Synthesis. Angewandte Chemie, 2021, 133, 19493-19503.	1.6	2